NOV 0 1 7002 US

SUBMISSION UNDER MPEP 609 D

Application Number	10/081,943
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ORT-1578

Page 1 of 1

			U.S. PA	TENT DOCUMENTS	 		
	aminer	Cite	Name of Patentee or Applicant of Cited Document	U.S. Patent Document Number	d Code ² known)	Pages, Columns, Lines, where relevant passages or relevant figures appear	
12	28 /		Ortho-McNeil Pharmaceutical, Inc.	09/906,251			
	TV		Ortho-McNeil Pharmaceutical, Inc.	10/081,501		RECEIV	/ED
			Ortho-McNeil Pharmaceutical, Inc.	10/081,766		ILOLIV	
			Ortho-McNeil Pharmaceutical, Inc.	10/081,606		NOV 0 8 20	002
			Ortho-McNeil Pharmaceutical, Inc.	10/081,761		TECH CENTER 16	<u> </u>
			Ortho-McNeil Pharmaceutical, Inc.	10/081,713		1 TO 11 OF MITH 10	JU/2500
			Ortho-McNeil Pharmaceutical, Inc.	10/193,600			
	11		Ortho-McNeil Pharmaceutical, Inc.	10/192,973	 		
	W		Ortho-McNeil Pharmaceutical, Inc.	10/081,764			
				DATELIT DOGLINGELITO			

		- TOKLIGI	TEATER	DOCUMENT	<u> </u>		
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreign Pa	atent Document	indCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T⁵
				-			
				1			
				 			
				<u> </u>	 		
				 	ļ		
		OTHER PRIOR ART - N	ON PATENT	LITERATURE	DOCUMEN	ITS	·
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					T²		
7/1	<u> </u>	Search Report for PCT/US 02/05421 do	ated July 1, 2	2002			
7							
				·			
				· · · · · · · · · · · · · · · · · · ·			
							
							 -

Examiner Signature	WILLIAM R. A. JARVIS	Date Considered	\$ 2/	23/03	
	PRIMARY EXAMINER				



NOV 0 7 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number 10/081,943

Filing Date February 21, 2002

First Named Inventor Carlos R. Plata-Salaman

Group Art Unit 1614

Examiner Name unknown

Attorney Docket Number ORT-1578

			01 1 01 2			
				U.S. PATENT DOCUMENTS		
Examiner . Initials	Cite	U.S. Patent Do	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
-(8)	NO.		(ii known)		mm-dd-yyyy	or relevant figures appea
2		3,278,380	Α	Bossinger et al.	10/11/1966	
7		3,265,728	Α	Bossinger et al.	8/9/1966	
		6,103,759	A	Choi et al.	8/15/2000	
		-				
					 	
						
		<u>-</u>				
		1				

	FOREIGN PATENT DOCUMENTS							
		Foreign	Patent Documer	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number ⁴ Kir	dCode⁵	Applicant of Cited Document	mm-dd-yyyy passages or releva		τ⁰
250	<u> </u>	wo	02/07822	A2	Ortho-McNeil Pharmaceutical, Inc.	1/31/2002		
			,					

EODEIGN DATENT DOCUMENTS


E			· · · · · · · · · · · · · · · · · · ·	
Examiner		Doto		
Cimpoture	bank kan be by a samker	Date	17/22/27	
Signature	WILLIAM R. A. JARVIS	Considered	12/25/25	
		Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference consider PRIMACHEMATIMERation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.





TECH CENTER 1600/2900 PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a valid OMB control number.				
Application Number	10/081,943			
Filing Date	February 21, 2002			
First Named Inventor	Carlos R. Plata-Salaman			
Group Art Unit	1614			
Examiner Name	unknown			
Attorney Docket Number	ORT-1578			

F			OTHER DRIVE ARY MONEY TENE	
ŀ			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
			Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
1	Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
- 11	Initials*	No.1	publisher, city and/or country where published	,
II.	~ 78T		ETTORE B., The Use of Anticonvulsants in Neurological Conditions Other than Epilepsy. A Review of the Evidence from	
1	DC.	<u> </u>	Randomized Controlled Trials; CNS Drugs, 1999; pp. 61-81; Vol. 11, No. 1	
	1		HANSEN, H. C.; Treatment of Chronic Pain with Antiepileptic Drugs: A New Era; Southern Medical Journal; July 1999; pp.	
-	<u> </u>		1 642-649 Vol 92 No 7	
			MAGNUS, L.; Nonepileptic uses of Gabapentin; Epilepsia: 1999; pp. S66-S72; Vol. 40 [Suppl. 6]; Lippincott Williams & Wilkins, Philadelphia	
	1		SWERDLOW, M.; Anticonvulsant Drugs and Chronic Pain; Clinical Neuropharmacology, 1984; pp. 51-82; Vol. 7, No. 1; Raven Press, New York	
L	W/		WiLEMAN, L.; Advances in Pain Management, Scrip Report; February 28, 2000; PJB Publications, Ltd.	
IL	ч			
iL				
10				
IJ.				
ı				
▐	_			
╟				
╟	···	-		
╟				
⊩				
╟		LI		
╟				
IL				
IL				
П				
Г				
1				
╟				
╟				
╟				
⊩				
L				

Examiner Signature	WILLIAM R. A. JARVIS	Date Considered	2/23/03
	PRIMARY FXAMINER		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.